Salwender, H., Bertsch, U., Benner, A., Raab, M., Hillengaß, J., Hose, D., . . . Goldschmidt, H. (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: A randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BioMed Central.
Chicago-Zitierstil (17. Ausg.)Salwender, Hans, et al. Rationale and Design of the German-speaking Myeloma Multicenter Group (GMMG) Trial HD6: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction/consolidation and Lenalidomide Maintenance in Patients with Newly Diagnosed Myeloma. London: BioMed Central, 2019.
MLA-Zitierstil (9. Ausg.)Salwender, Hans, et al. Rationale and Design of the German-speaking Myeloma Multicenter Group (GMMG) Trial HD6: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction/consolidation and Lenalidomide Maintenance in Patients with Newly Diagnosed Myeloma. BioMed Central, 2019.